I n this period, a novel therapeutic is in phase 3 development for allergic conjunctivitis, and there are numerous business arrangements for ophthalmic products including 2 biosimilar candidates for intravitreal dosing for wet age-related macular degeneration and dry eye. The FDA modified published guidance on the manufacture and distribution of homeopathic drugs. A contact lens was approved to slow the progression of myopia in children, and a patient was treated with stem cells for limbal stem cell deficiency (LSCD).
Ophthalmic Pharmaceuticals and Biologics
Aerie Pharmaceuticals received marketing authorization from the European Commission for Rhokiinsa Ò (netarsudil ophthalmic solution) 0.02% for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension (November 2019). The firm also reported results from a dose-response study of netarsudil in patients with ocular hypertension and glaucoma in Japan (November 2019). The firm will be acquiring Avizorex Pharma, S.L., a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease (November 2019). Aldeyra Therapeutics will initiate a phase 3 trial of topical ocular reproxalap for the treatment of allergic conjunctivitis (November 2019). Clearside Biomedical licensed its XIPEREÔ (triamcinolone acetonide suprachoroidal injectable suspension) to Bausch Health (November 2019). Genentech announced the FDA has accepted the company's biologics license application for satralizumab for the treatment of adults and adolescents with neuromyelitis optica spectrum disorder. The European Medicines Agency granted an accelerated assessment for a Marketing Authorization Application for satralizumab in Europe (October 2019). Novaliq and Jiangsu Hengrui Medicine announced a licensing agreement for its NOV03 and CyclASol for the treatment of dry eye disease in China (October 2019). Oyster Point Pharma announced results from their phase 1 ''ZEN'' study in healthy volunteers evaluating the systemic bioavailability of varenicline nasal spray (OC-01) after nasal administration (November 2019). Samsung Bioepis entered into an agreement with Biogen for 2 biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept) in major markets. SB11 is in phase 3 clinical trials and SB15 is in preclinical development (November 2019).
Gene and Cell Therapy
Chiesi treated the first patient with its stem cell-based therapy, Holoclar, a layer of cells grown in the laboratory from patient biopsy material. The indication is treatment of LSCD caused by chemical eye burns (November 2019). ProQR received U.S. FDA rare pediatric designation for the treatment of Leber's congenital amaurosis 10 with its drug, sepofarsen (October 2019).
Medical Devices
CooperVision received FDA approval for the first contact lens indicated to slow the progression of myopia (nearsightedness) in children. The product, MiSightÔ, is a single use daily disposable soft contact lens (November 2019).
Regulatory, Government, and Pharmaceutical Industry
A 1989 article touted by creationists as evidence of their beliefs, long critiqued by others, 1 was retracted by the journal due to the unreliable nature of the experimental results. 2 According to an analysis by the Wall Street Journal, the U.S. FDA has approved 2,492 generic versions of 617 brand-name drugs since 2016. However, only approximately half (1,249) of these generic products were launched into the market (November 2019). 3 Alnylam received U.S. FDA approval for Givlaari (givosiran), the second-ever drug based on RNA interference. The product is intended from monthly subcutaneous injection to treat acute hepatic porphyria (November 2019).
In a position statement contrary to a statement from the American Academy of Neurology, Masdeu et al. argue that the practice of physician-hastened death is contrary to the interests of patients, their families, and the sound ethical practice of medicine (November 2019). 4 Novartis received FDA approval for Ziextenzo (pegfilgrastim-bmez), a leukocyte growth factor biosimilar version of Amgen's Neulasta Ò (pegfilgrastim) to decrease the incidence of infection, as manifested by febrile neutropenia, in selected patients being treated for cancer. The firm also received U.S. FDA approval for Adakveo Ò (crizanlizumab, SEG101), to reduce the frequency of vaso-occlusive crises, or pain crises, in adult and pediatric patients aged 16 years and older with sickle cell disease (November 2019). The FDA modified published guidance on the manufacture and distribution of homeopathic drugs (October 2019). 5 The U.S. Centers for Disease Control (CDC) and the FDA are investigating a multistate outbreak of e-cigarette, or vaping, product use associated lung injury. Preliminary analyses of bronchoalveolar lavage fluid samples of patients with product use-associated lung injury identified vitamin E acetate (November 2019).
